FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns a composition for subcutaneous administration, containing PEGylated interferon alpha and additives, particularly edetate disodium dehydrate, sodium acetate trihydrate, glacial acetic acid, an osmotic agent. The group of inventions also concerns a method for producing the above composition; a kit comprising a syringe or flask filled with the above composition, and an instruction for use.
EFFECT: group of inventions provides less painful administration of the composition.
15 cl, 7 ex, 5 dwg, 13 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PEG-MODIFIED HUMAN INTERFERON β-1a MOLECULE WITH ANTIVIRAL, IMMUNOMODULATORY AND ANTIPROLIFERATIVE ACTIVITY, WITH IMPROVED STABILITY, REDUCED IMMUNOGENICITY, IMPROVED PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS, SUITABLE FOR MEDICAL USE, AND IMMUNOBIOLOGICAL FORMULATION BASED THEREON | 2013 |
|
RU2576372C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
| RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
| INTERFERON AN AQUEOUS SOLUTION | 1996 |
|
RU2113845C1 |
| MEDICINAL AGENT BASED ON MODIFIED ALPHA INTERFERON WITH PROLONGED THERAPEUTIC ACTION | 2008 |
|
RU2382048C1 |
| NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON | 2010 |
|
RU2447083C1 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND THE USE THEREOF | 2020 |
|
RU2745814C1 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTIBODY TO PD-1 OF PROLGOLIMAB AND ITS USE | 2019 |
|
RU2806320C2 |
| ANESTHETIC COMPOSITION AND METHOD OF EYE ANESTHETIZATION | 2020 |
|
RU2812900C2 |
| NEW FUNCTIONAL, HIGH-PURITY STABLE CONJUGATE OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) AND POLYETHYLENE GLYCOL WITH PROLONGED BIOLOGICAL ACTION, APPLICABLE FOR MEDICAL PURPOSES, AND BASED IMMUNOBIOLOGICAL AGENT | 2010 |
|
RU2446173C1 |
